What Is Biocognate?

"BIO"

"COGNATE"

Living

Generically Alike

Together the two words deliver the essence of what we intend to achieve and hence we call ourselves
“BioCognate LifeSciences”

Biosimilar products provide an affordable option for millions of patients across the globe to access best-in-class biologics to treat serious life-threatening diseases. Governments of several countries including developed economies are pushing for reducing health care cost by encouraging the development of less expensive biosimilars through regulatory reforms. Biosimilars market is experiencing consistent growth expected to be sustained over several years fuelled through opening of un-met markets as the affordability for these drugs enhances.

Why Biocognate?

Offers entire biosimilars product development solution under one roof

Biosimilar Development Overview

Company Overview

Biocognate Life Sciences Pvt. Ltd. was established with the sole vision of supporting biosimilars development and for the past two years has been engaged in dissipation of technical knowhow in the domain.

Biocognate extends its services in the form of developing and supplying high quality recombinant biosimilar product cell lines along with easily scalable process and analytical methodologies to its partners in the biopharma community who are interested in clinical and commercial development of biosimilars.

Unlike the standard CRO/CMO offerings, Biocognate plans to offer off-the-shelf, biosimilar product cell line and processes at R&D scale. By offering a pipeline of ready to scale up biosimilar cell lines with lab-scale processes, we ensure significant reduction in the timeline of product development for our partners, thereby, radically increasing the speed to clinic and accessibility of the product to patients.

  • Vision

    To emerge as a trustworthy global biopharma organization delivering high-quality cell-lines and process technology data packages for biosimilars, thereby enabling affordable access to biologics medication to the patients across the world.

  • Mission

    To create a science-driven organization that supports biosimilars eco-system by providing regulatory-compliant, high-quality biosimilar product packages to the Biopharma industry thus accelerating their access to patients.

  • Values

Use highest standard of science and technology as pillars to create biosimilar product packages.

To abide with the basic tenets of quality adherence in every single action/task and deliverable.

Our Capabilities

Cell Line Development

Biocognate’s cell line development protocols leverage more than four decades of experience of its expert 

Read More

Process Development:

Biocognate has the expertise to develop robust, reproducible, and seamlessly scalable processes that can allow the customers to reach process scale-up 

Read More..

Analytical Development

Analytical development would include development of the basic processes required for demonstrating content, product related 

Read More..

Cell Line Development

Biocognate’s cell line development protocols leverage more than four decades of experience of its expert team involved in developing recombinant clones for regulated markets.

Read more

Process Development

Biocognate has the expertise to develop robust, reproducible, and seamlessly scalable processes that can allow the customers to reach process scale-up for clinical development quickly.

Read more

Analytical Development

Analytical development would include development of the basic processes required for demonstrating content, product related impurities (such as charge variants, aggregation) and general.

Read more

Meet The Team

Samir Kulkarni, PhD

Director and founder of Biocognate Life Sciences Pvt. Ltd.

Samir founded Biocognate in 2020 with a vision to establish a core science driven organization that enables..
Read More..

Prasad Krishnamurthy, PhD

Director and Co-founder of Biocognate Life Sciences Pvt. Ltd

Prasad is a co-founder of Biocognate and brings more than 18 years of experience in scientific research both in India and US.
Read More..